Glenmark Pharmaceuticals

The company informed exchanges that it has received the EIR from the US FDA for its formulations manufacturing facility in Monroe, North Carolina, with a Voluntary Action Indicated (VAI) status

Stocks to buy: Ajit Mishra of Religare Broking recommends buying Axis Bank, Glenmark Pharma, and United Spirits; also suggests Nifty trading strategy

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Glenmark Pharmaceuticals Ltd on Friday reported a 72.2 per cent jump in consolidated profit after tax at Rs 610.43 crore in the second quarter ended September 2025 on the back of its licensing deal with AbbVie for investigational asset 'ISB 2001'. The company had posted a consolidated profit after tax (PAT) of Rs 354.49 crore in the corresponding period last fiscal, Glenmark Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations was at Rs 6,046.87 crore as against Rs 3,433.8 crore in the same period a year ago, it added. Total expenses in the quarter under review were at Rs 3,894.98 crore as against Rs 3,000.64 crore in the same period last fiscal, the company said. "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the

Q2FY26 company results: Firms including Exide Industries, MRF, Siemens, Glenmark Pharma, and Inox Wind are also to release their July-September earnings reports today

Glenmark's Ryaltris nasal spray, already approved in the US, EU and other markets, has now secured China's NMPA approval, strengthening its global respiratory portfolio

Glenmark Pharmaceuticals Ltd on Monday said its arm Glenmark Specialty SA has received approval from China's National Medical Products Administration for the nasal spray RYALTRIS used to treat allergic rhinitis. The National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children -- specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adults and pediatric patients 12 years of age and older, the company said in a statement. The approval granted with zero supplementation requests is an important milestone in Glenmark's respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions, it added. "The approval of RYALTRIS in China is a significant step in expanding our specialty respiratory ...

The product is approved as bioequivalent and therapeutically equivalent to the reference listed drug, Naropin Injection, marketed by Fresenius Kabi USA LLC

Domestic drugmakers Glenmark, Granules India, Sun Pharma, Zydus and Unichem are recalling products in the US market for various manufacturing issues, according to the US Food and Drug Administration (USFDA). The drugmakers are voluntarily recalling affected lots in the American market, the US health regulator said in its latest Enforcement Report. A US-based subsidiary of the Mumbai-based Glenmark Pharmaceuticals is recalling 13,824 Azelaic Acid Gel tubes produced at the company's Goa plant due to "CGMP deviations" following market complaints received for gritty texture, USFDA said. New Jersey-based Glenmark Pharmaceuticals Inc, USA, initiated the Class II nationwide recall on September 17. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. Hyderabad-based Granules India is recalling over 49,000

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets

Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion

The buying on the counter came after the company's subsidiary Ichnos Glenmark Innovation received an upfront payment of $700 million from AbbVie

Glenmark Pharmaceuticals on Friday said it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel drug for third-stage non-small cell lung cancer. The company said it has received approval from the Drugs Controller General of India to begin patient enrolment and dosing in the country. In parallel, the drug firm has submitted a clinical trial application in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, Glenmark said in a statement. The randomised, multi-centre, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with third-stage non-small cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC comprising around 80-85 per cent of cases. "By advancing this trial across multiple geographies, we are reinforcing our commitment to transforming the standard of care in Stage III NSCLC and addressing one of the grea

Around 11:20 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 3.05 per cent at ₹2,051.40 per share. In comparison, BSE Sensex was trading 0.25 per cent lower at 80,518.51 levels.

Markets edged higher and gained over half a percent, supported by optimism surrounding the GST Council meeting.

Recently Nykaa stock had given a breakout on the weekly charts with high volumes. In last few days the stock gradually moved higher and showed relative strength when the markets were correcting.

Glenmark Pharma stock has tanked over 5 per cent after the company reported lower-than-expected performance in the June 2025 quarter, missing market estimates